Prosecution Insights
Last updated: November 04, 2026
Application No. 18/285,090

METHOD FOR MEASURING AGGREGATING PROTEINS, METHOD FOR VISUALIZING AGGREGATION, AND KIT USED THEREFOR

Non-Final OA §103§112
Filed
Sep 29, 2023
Priority
Mar 31, 2021 — JP 2021-061500 +2 more
Examiner
MEAH, MOHAMMAD Y
Art Unit
1652
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Muroran Institute Of Technology
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
695 granted / 983 resolved
+10.7% vs TC avg
Strong +43% interview lift
Without
With
+42.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
65 currently pending
Career history
1023
Total Applications
across all art units

Statute-Specific Performance

§101
4.2%
-35.8% vs TC avg
§103
26.2%
-13.8% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
39.9%
-0.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 983 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detail Action Claims 1-21 are pending for examination. Applicants’ election on 8/17/2026 with traverse of group III (claims 15-20) directed to a method for visualizing an aggregate of aggregating proteins comprising visualizing an aggregate of aggregating proteins in the aggregating protein- containing solution collected by the method according to claim 1, in their response against the restriction requirement of 6/17/2026 is acknowledged. Traversal on the ground that no undue burden on the examiner to examine all the claims is considered but found unpersuasive because group I-II claims and group IV claim belong to different class of invention than that of elected group III claims and searching one class of invention would not encompass other claims of invention. Claims 1-14 and 21 comprise non elected subjected are withdrawn. Claims 15-20 are for examination. Election made final. Information Disclosure Statement The information disclosure statement (IDS) submitted on 9//29/2023, 10//10/2023 , 4//29/2026 in compliance with the provisions of 37 CFR 1.97. Accordingly, the examiner has considered the IDS statement. Claim Objection Claim 15 is objected for depending on withdrawn claim 1. It should be written as an independent claim. Correction is required. Claim Rejections: 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. claims 15, 19, 16-20( depends on claim 15) are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention Claim 15 is indefinite in reciting “method for visualizing an aggregate of aggregating proteins comprising visualizing an aggregate of aggregating proteins in the aggregating protein- containing solution collected by the method according to claim 1” because claim 15 comprise a method of visualizing an aggregate of aggregating proteins – a product that produce by another method ( method of claim 1) comprising multiple steps which make claim remain vague and indefinite because It is unclear if each of the argued "product by process steps ( processes of claim 1) of claim 15" are intended in the alternative, are all required, or are conditional in nature. Correction required. Claim 19 is indefinite in reciting “the label” for lacking antecedent basis. Claim 19 depends on claim 16. Claim 16 recite partially labeled aggregating proteins not a label. Correction required. Claim Rejections: 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. According to MPEP 2143:"Exemplary rationales that may support a conclusion of obviousness include:(A) Combining prior art elements according to known methods to yield predictable results;(B) Simple substitution of one known element for another to obtain predictableresults;(C) Use of known technique to improve similar devices (methods, or products) in the same way;(D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results;(E) "Obvious to try" - choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success;(F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art;(G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention.Note that the list of rationales provided is not intended to be an all-inclusive list. Other rationales to support a conclusion of obviousness may be relied upon by Office personnel." Claims 15 is rejected under 35 U.S.C. 103(a) as being unpatentable over Claims as being anticipated by Enki et al. ( JP2005139104A1, 02 June 2005 (2005-06-02), pages 1-22. IDS) in view of Nakamura et al. ( JP2017007990A1, 2017,IDS ). Enki et al. discloses the method for separating and cooling prion protein comprises a process for filtering a prion protein solution through a membrane filter composed of a porous hollow fiber through which a solid smaller than prion protein is passed and a process for releasing prion protein from the membrane filter by reversely sending a recovery solution not to coagulate prion protein to the membrane filter( abstract). (collecting an aggregating protein-containing solution comprising: a first step of allowing a solution for accelerating and visualizing protein aggregation to pass through a filtration filter; and a second step of allowing an aggregating protein-containing solution to pass through the filtration filter through which the solution for accelerating and visualizing protein aggregation has passed. Claim 1.) Enki et al. do not disclose said method for visualizing an aggregate of aggregating proteins comprising visualizing an aggregate of aggregating proteins in the aggregating protein- containing solution collected by visualization using a label. Nakamura et al. ( JP2017007990A1, 2017, ) discloses a quantum dot nano probe (universal probe) that has wide interactive spectrum to amyloid fibrils of amyloidogenic protein or peptide being a causative substance of Amyloidosis. Therefore it would have been obvious to a person of ordinary skill in the art, at the time of the instant invention is filled to combine the teaching of Enki et al. and Nakamura et al. to Enki et al. to further visualization of aggregate of aggregating proteins in the aggregating protein- containing solution using a quantum dot nano probe label. Conclusion Claims 15-20 are rejected and no claim is allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272- 1261. The examiner can normally be reached on 8:30-5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert Mondesi can be reached on 4089187584. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system. /MOHAMMAD Y MEAH/Examiner, Art Unit 1652
Read full office action

Prosecution Timeline

Sep 29, 2023
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753216
BIOACTIVE AGENTS AND METHODS RELATED THERETO
4y 10m to grant Granted Oct 06, 2026
Patent 12747262
ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS
2y 6m to grant Granted Sep 29, 2026
Patent 12735446
ALKOXYPHENYL DERIVATIVES, PROTECTED NUCLEOSIDES AND PROTECTED NUCLEOTIDES, METHOD FOR PRODUCING OLIGONUCLEOTIDES, AND METHOD FOR REMOVING SUBSTITUENTS
2y 6m to grant Granted Sep 15, 2026
Patent 12698505
EUKARYOTIC HOST SYSTEM FOR PRODUCING RECOMBINANT PROTEINS
4y 10m to grant Granted Aug 04, 2026
Patent 12697348
COMPOSITIONS FOR PROMOTING LONGEVITY AND METHODS OF USING THE SAME
2y 5m to grant Granted Aug 04, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+42.9%)
3y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 983 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month